Cart
0

Antibiotics Market by Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, and Others), Drug Origin (Natural, Semisynthetic, and Synthetic), Spectrum of Activity (Broad-spectrum Antibiotic and Narrow-spectrum Antibiotic), and Route of Administration (Oral, Intravenous, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Get 20% Free Customization In This Report
LI_185072
Pages: 282
Oct 2018 | 474 Views
 
Author's : Onkar Sumant, Tenzin Kunsel, and Surabhi Pandey
Tables: 140
Charts: 54
 

Antibiotics Market Overview :

Antibiotic is an antimicrobial substance, which combats bacterial infections and occasionally protozoan infections. In addition, they are used to cure several diseases such as strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, ear infections, and others. There are numerous ways of classifying antibiotics, however, the most common classification is based on their chemical structures, spectrum of activity, and mode of action. Currently, the demand for beta lactam and beta lactamase inhibitors class of antibiotics is high among healthcare providers. The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.

The growth of the global antibiotics market is increasing due to increased consumption of antibiotics in low & middle-income countries, major investments in R&D activities by pharmaceutical companies, and rise in prevalence of infectious diseases. However, development of antibiotic resistance and increase in drug approval costs are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer remunerative opportunities for market players.

Get more information on this report: Request Sample Pages

Class segment review

Based on class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors segment is further divided into penicillin, cephalosporin, carbapenem, and monobactam. The beta lactam & beta lactamase inhibitors segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period. This is attributed to its broad-spectrum activity, which heals infections caused due to multiple groups of bacteria. Thus, the demand for beta lactam & beta lactamase inhibitors is high among the healthcare providers and patients, which in turn fuels the growth of the global antibiotics market.

Get more information on this report: Request Sample Pages

Spectrum of activity segment review

Based on the spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. The broad-spectrum antibiotic segment is projected to exhibit the highest growth during the forecast period. This is attributed to the fact that broad-spectrum antibiotics act against a wide range of diseases, which in turn helps to combat antimicrobial resistance.

Get more information on this report: Request Sample Pages

Region segment review

Region wise, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increased consumption of antibiotics, their easy availability, and rise in sale of over-the-counter drugs.

The report provides a comprehensive analysis of the key players operating in the global antibiotics market, namely, Abbott Laboratories, Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Aurobindo Pharma, Bayer HealthCare, Eli Lilly, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, and others.

Key Benefits for Antibiotics Market :

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.

  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

  • A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.

  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

Antibiotics Key Market Segments :

  • By Class

    • Beta Lactam & Beta Lactamase Inhibitors

      • Penicillin

      • Cephalosporin

      • Carbapenem

      • Monobactam

    • Quinolone

    • Macrolide

    • Others

  • By Drug Origin

    • Natural

    • Semisynthetic

    • Synthetic

  • By Spectrum of Activity

    • Broad-spectrum Antibiotic

    • Narrow-spectrum Antibiotic

  • By Route of Administration

    • Oral

    • Intravenous

    • Others

  • By Region

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • Germany

      • France

      • Spain

      • Italy

      • UK

      • Rest of Europe

    • Asia-Pacific

      • Australia

      • Japan

      • India

      • China

      • Rest of Asia-Pacific

    • LAMEA

      • Brazil

      • Saudi Arabia

      • South Africa

      • Rest of LAMEA

 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.3.1. Top winning strategies

3.4. Market share analysis, 2017
3.5. Porters five forces analysis

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increased consumption in low and middle-income countries (LMICs)
3.6.1.2. Rising prevalence of infectious diseases
3.6.1.3. Development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials.

3.6.2. Restraints

3.6.2.1. Development of Antibiotic resistance, driven by misuse of antibiotics
3.6.2.2. The time taken for the regulatory approval

3.6.3. Opportunities

3.6.3.1. Discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections.

Chapter: 4: ANTIBIOTICS MARKET, BY CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Beta Lactam and Beta Lactamase Inhibitors

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Penicillins

4.2.2.1.1. Market size and forecast

4.2.2.2. Cephalosporins

4.2.2.2.1. Market size and forecast

4.2.2.3. Carbapenems

4.2.2.3.1. Market size and forecast

4.2.2.4. Monobactams

4.2.2.4.1. Market size and forecast

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Quinolones

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Macrolides

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

Chapter: 5: ANTIBIOTICS MARKET, BY DRUG ORIGIN

5.1. Overview

5.1.1. Market size and forecast

5.2. Natural

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Semisynthetic

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Synthetic

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

Chapter: 6: ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY

6.1. Overview

6.1.1. Market size and forecast

6.2. Broad-spectrum antibiotic

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Narrow-spectrum antibiotic

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

Chapter: 7: ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.1.1. Market size and forecast

7.2. Oral

7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country

7.3. Intravenous

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

7.4. Others

7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country

Chapter: 8: ANTIBIOTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends and opportunities
8.2.2. North America antibiotics market, by country

8.2.2.1. U.S. antibiotics market by class
8.2.2.2. U.S. antibiotics market by drug origin
8.2.2.3. U.S. antibiotics market by spectrum of activity
8.2.2.4. U.S. antibiotics market by Route of administration
8.2.2.5. Canada antibiotics market by class
8.2.2.6. Canada antibiotics market by drug origin
8.2.2.7. Canada antibiotics market by spectrum of activity
8.2.2.8. Canada antibiotics market by route of administration
8.2.2.9. Mexico antibiotics market by class
8.2.2.10. Mexico antibiotics market by drug origin
8.2.2.11. Mexico antibiotics market by spectrum of activity
8.2.2.12. Mexico antibiotics market by route of administration

8.2.3. North America antibiotics market, by class
8.2.4. North America antibiotics market, by drug origin
8.2.5. North America antibiotics market, by spectrum of activity
8.2.6. North America antibiotics market, by route of administration

8.3. Europe

8.3.1. Key market trends and opportunities
8.3.2. Europe antibiotics market, by country

8.3.2.1. Germany antibiotics market by class
8.3.2.2. Germany antibiotics market by drug origin
8.3.2.3. Germany antibiotics market by spectrum of activity
8.3.2.4. Germany antibiotics market by Route of administration
8.3.2.5. France antibiotics market by class
8.3.2.6. France antibiotics market by drug origin
8.3.2.7. France antibiotics market by spectrum of activity
8.3.2.8. France antibiotics market by route of administration
8.3.2.9. Spain antibiotics market by class
8.3.2.10. Spain antibiotics market by drug origin
8.3.2.11. Spain antibiotics market by spectrum of activity
8.3.2.12. Spain antibiotics market by route of administration
8.3.2.13. Italy antibiotics market by class
8.3.2.14. Italy antibiotics market by drug origin
8.3.2.15. Italy antibiotics market by spectrum of activity
8.3.2.16. Italy antibiotics market by route of administration
8.3.2.17. UK antibiotics market by class
8.3.2.18. UK antibiotics market by drug origin
8.3.2.19. UK antibiotics market by spectrum of activity
8.3.2.20. UK antibiotics market by route of administration
8.3.2.21. Rest of Europe antibiotics market by class
8.3.2.22. Rest of Europe antibiotics market by drug origin
8.3.2.23. Rest of Europe antibiotics market by spectrum of activity
8.3.2.24. Rest of Europe antibiotics market by route of administration

8.3.3. Europe antibiotics market, by class
8.3.4. Europe antibiotics market, by drug origin
8.3.5. Europe antibiotics market, by spectrum of activity
8.3.6. Europe antibiotics market, by route of administration

8.4. Asia-Pacific

8.4.1. Key market trends and opportunities
8.4.2. Asia-Pacific antibiotics market, by country

8.4.2.1. Australia antibiotics market by class
8.4.2.2. Australia antibiotics market by drug origin
8.4.2.3. Australia antibiotics market by spectrum of activity
8.4.2.4. Australia antibiotics market by Route of administration
8.4.2.5. Japan antibiotics market by class
8.4.2.6. Japan antibiotics market by drug origin
8.4.2.7. Japan antibiotics market by spectrum of activity
8.4.2.8. Japan antibiotics market by route of administration
8.4.2.9. India antibiotics market by class
8.4.2.10. India antibiotics market by drug origin
8.4.2.11. India antibiotics market by spectrum of activity
8.4.2.12. India antibiotics market by route of administration
8.4.2.13. China antibiotics market by class
8.4.2.14. China antibiotics market by drug origin
8.4.2.15. China antibiotics market by spectrum of activity
8.4.2.16. China antibiotics market by route of administration
8.4.2.17. Rest of Asia-Pacific antibiotics market by class
8.4.2.18. Rest of Asia-Pacific antibiotics market by drug origin
8.4.2.19. Rest of Asia-Pacific antibiotics market by spectrum of activity
8.4.2.20. Rest of Asia-Pacific antibiotics market by route of administration

8.4.3. Asia-Pacific antibiotics market, by class
8.4.4. Asia-Pacific antibiotics market, by drug origin
8.4.5. Asia-Pacific antibiotics market, by spectrum of activity
8.4.6. Asia-Pacific antibiotics market, by route of administration

8.5. LAMEA

8.5.1. Key market trends and opportunities
8.5.2. LAMEA antibiotics market, by country

8.5.2.1. Brazil antibiotics market by class
8.5.2.2. Brazil antibiotics market by drug origin
8.5.2.3. Brazil antibiotics market by spectrum of activity
8.5.2.4. Brazil antibiotics market by Route of administration
8.5.2.5. Saudi Arabia antibiotics market by class
8.5.2.6. Saudi Arabia antibiotics market by drug origin
8.5.2.7. Saudi Arabia antibiotics market by spectrum of activity
8.5.2.8. Saudi Arabia antibiotics market by route of administration
8.5.2.9. South Africa antibiotics market by class
8.5.2.10. South Africa antibiotics market by drug origin
8.5.2.11. South Africa antibiotics market by spectrum of activity
8.5.2.12. South Africa antibiotics market by route of administration
8.5.2.13. Rest of LAMEA antibiotics market by class
8.5.2.14. Rest of LAMEA antibiotics market by drug origin
8.5.2.15. Rest of LAMEA antibiotics market by spectrum of activity
8.5.2.16. Rest of LAMEA antibiotics market by route of administration

8.5.3. LAMEA antibiotics market, by class
8.5.4. LAMEA antibiotics market, by drug origin
8.5.5. LAMEA antibiotics market, by spectrum of activity
8.5.6. LAMEA antibiotics market, by route of administration

Chapter: 9: COMPANY PROFILES

9.1. Abbott Laboratories

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance

9.2. Allergan Plc.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments

9.3. F. Hoffmann-La Roche Ltd.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments

9.4. GlaxoSmithKline plc

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. Merck & Co. Inc.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. Mylan N.V.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance
9.6.6. Key strategic moves and developments

9.7. Novartis International AG (Sandoz)

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance

9.8. Pfizer Inc.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments

9.9. Sanofi

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. Teva Pharmaceutical Industries Ltd.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL ANTIBIOTICS MARKET, BY CLASS, 20172025 ($MILLION)
TABLE 02. BETA LACTAM AND BETA LACTAMASE INHIBITORS ANTIBIOTICS MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 03. ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY REGION, 20172025 ($MILLION)
TABLE 04. ANTIBIOTICS MARKET FOR QUINOLONES, BY REGION, 20172025 ($MILLION)
TABLE 05. ANTIBITOTICS MARKET FOR MACROLIDES, BY REGION, 20172025 ($MILLION)
TABLE 06. ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 07. GLOBAL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 20172025 ($MILLION)
TABLE 08. ANTIBIOTICS MARKET FOR NATURAL, BY REGION, 20172025 ($MILLION)
TABLE 09. ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY REGION, 20172025 ($MILLION)
TABLE 10. ANTIBIOTICS MARKET FOR SYNTHETIC, BY REGION, 20172025 ($MILLION)
TABLE 11. GLOBAL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 20172025 ($MILLION)
TABLE 12. ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ANTIBIOTIC, BY REGION, 20172025 ($MILLION)
TABLE 13. ANTIBIOTICS MARKET FOR NARROW-SPECTRUM ANTIBIOTIC, BY REGION, 20172025 ($MILLION)
TABLE 14. GLOBAL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 20172025 ($MILLION)
TABLE 15. ANTIBIOTICS MARKET FOR ORAL, BY REGION, 20172025 ($MILLION)
TABLE 16. ANTIBIOTICS MARKET FOR INTRAVENOUS, BY REGION, 20172025 ($MILLION)
TABLE 17. ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 18. GLOBAL ANTIBIOTICS MARKET REVENUE, BY REGION, 20172025 ($MILLION)
TABLE 19. NORTH AMERICA ANTIBIOTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 20. U.S. ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 21. U.S. ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 22. U.S. ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 23. U.S. ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 24. CANADA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 25. CANADA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 26. CANADA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 27. CANADA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 28. MEXICO ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 29. MEXICO ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 30. MEXICO ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 31. MEXICO ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 32. NORTH AMERICA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 33. NORTH AMERICA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 34. NORTH AMERICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 35. NORTH AMERICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 36. EUROPE ANTIBIOTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 37. GERMANY ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 38. GERMANY ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 39. GERMANY ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 40. GERMANY ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 41. FRANCE ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 42. FRANCE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 43. FRANCE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 44. FRANCE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. SPAIN ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 46. SPAIN ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 47. SPAIN ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 48. SPAIN ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 49. ITALY ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 50. ITALY ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 51. ITALY ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 52. ITALY ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 53. UK ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 54. UK ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 55. UK ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 56. UK ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 57. REST OF EUROPE ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 58. REST OF EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 59. REST OF EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 60. REST OF EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 61. EUROPE ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 62. EUROPE ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 63. EUROPE ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 64. EUROPE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 65. ASIA-PACIFIC ANTIBIOTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 66. AUSTRALIA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 67. AUSTRALIA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 68. AUSTRALIA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 69. AUSTRALIA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 70. JAPAN ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 71. JAPAN ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 72. JAPAN ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 73. JAPAN ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 74. INDIA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 75. INDIA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 76. INDIA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 77. INDIA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 78. CHINA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 79. CHINA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 80. CHINA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 81. CHINA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 86. ASIA-PACIFIC ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 87. ASIA-PACIFIC ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 88. ASIA-PACIFIC ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 89. ASIA-PACIFIC ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 90. LAMEA ANTIBIOTICS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 91. BRAZIL ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 92. BRAZIL ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 93. BRAZIL ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 94. BRAZIL ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 95. SAUDI ARABIA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 96. SAUDI ARABIA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 97. SAUDI ARABIA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 98. SAUDI ARABIA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 99. SOUTH AFRICA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 100. SOUTH AFRICA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 101. SOUTH AFRICA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 102. SOUTH AFRICA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 103. REST OF LAMEA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 104. REST OF LAMEA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 105. REST OF LAMEA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 106. REST OF LAMEA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 107. LAMEA ANTIBIOTICS MARKET, BY CLASS, 2017-2025 ($MILLION)
TABLE 108. LAMEA ANTIBIOTICS MARKET, BY DRUG ORIGIN, 2017-2025 ($MILLION)
TABLE 109. LAMEA ANTIBIOTICS MARKET, BY SPECTRUM OF ACTIVITY, 2017-2025 ($MILLION)
TABLE 110. LAMEA ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 111. ABBOTT: COMPANY SNAPSHOT
TABLE 112. ABBOTT: OPERATING SEGMENTS
TABLE 113. ABBOTT: PRODUCT PORTFOLIO
TABLE 114. ALLERGAN: COMPANY SNAPSHOT
TABLE 115. ALLERGAN: OPERATING SEGMENTS
TABLE 116. ALLERGAN: PRODUCT PORTFOLIO
TABLE 117. ROCHE: COMPANY SNAPSHOT
TABLE 118. ROCHE: OPERATING SEGMENTS
TABLE 119. ROCHE: PRODUCT PORTFOLIO
TABLE 120. GSK: COMPANY SNAPSHOT
TABLE 121. GSK: OPERATING SEGMENTS
TABLE 122. GSK: PRODUCT PORTFOLIO
TABLE 123. MERCK: COMPANY SNAPSHOT
TABLE 124. MERCK: OPERATING SEGMENTS
TABLE 125. MERCK: PRODUCT PORTFOLIO
TABLE 126. MYLAN: COMPANY SNAPSHOT
TABLE 127. MYLAN: OPERATING SEGMENTS
TABLE 128. ALLERGAN: PRODUCT PORTFOLIO
TABLE 129. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 130. NOVARTIS: OPERATING SEGMENTS
TABLE 131. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 132. PFIZER: COMPANY SNAPSHOT
TABLE 133. PFIZER: OPERATING SEGMENTS
TABLE 134. PFIZER: PRODUCT PORTFOLIO
TABLE 135. SANOFI: COMPANY SNAPSHOT
TABLE 136. SANOFI: OPERATING SEGMENTS
TABLE 137. SANOFI: PRODUCT PORTFOLIO
TABLE 138. TEVA: COMPANY SNAPSHOT
TABLE 139. TEVA: OPERATING SEGMENTS
TABLE 140. TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ANTIBIOTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN THE GLOBAL ANTIBIOTICS MARKET
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2017
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. MODERATE COMPETITIVE RIVALRY
FIGURE 12. PENICILLINS ANTIBIOTICS MARKET, 20172025 ($MILLION)
FIGURE 13. CEPHALOSPORINS ANTIBIOTICS MARKET, 20172025 ($MILLION)
FIGURE 14. CARBAPENEMS ANTIBIOTICS MARKET, 20172025 ($MILLION)
FIGURE 15. MONOBACTAMS ANTIBIOTICS MARKET, 20172025 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR BETA LACTAM AND BETA LACTAMASE INHIBITORS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF ANITBIOTICS MARKET FOR QUINOLONES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 18. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR MACROLIDES, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF ANITBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR NATURAL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR SEMISYNTHETIC, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR SYNTHETIC, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR BROAD-SPECTRUM ANTIBIOTIC, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 24. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR NARROW-SPECTRUM ANTIBIOTIC, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 25. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR ORAL, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 26. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR INTRAVENOUS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 27. COMPARATIVE ANALYSIS OF ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 ($MILLION)
FIGURE 28. ABBOTT: NET SALES, 20152017 ($MILLION)
FIGURE 29. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. ALLERGAN: NET SALES, 20152017 ($MILLION)
FIGURE 32. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. ROCHE: NET SALES, 20152017 ($MILLION)
FIGURE 34. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. GSK: NET SALES, 20152017 ($MILLION)
FIGURE 36. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 37. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. MERCK: NET SALES, 20152017 ($MILLION)
FIGURE 39. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. MYLAN: NET SALES, 20152017 ($MILLION)
FIGURE 42. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 43. NOVARTIS: NET SALES, 20152017 ($MILLION)
FIGURE 44. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 45. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 46. PFIZER: NET SALES, 20152017 ($MILLION)
FIGURE 47. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 48. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 49. SANOFI: NET SALES, 20152017 ($MILLION)
FIGURE 50. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 51. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 52. TEVA: NET SALES, 20152017 ($MILLION)
FIGURE 53. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 54. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

 

Antibiotic is a chemical compound of natural or semi-synthetic or synthetic origin, which inhibits the growth of bacteria and protozoans. Antibiotic is either produced by a microorganism (natural) or from a similar product produced wholly (synthetic) or partially (semisynthetic) by chemical synthesis.

The global antibiotics market is expected to exhibit significant growth during the forecast period, due to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials supplement the market growth. However, low investment in R&D for the development of new antibiotics, time taken for regulatory approval, and increase in drug approval costs are expected to hinder the growth of the market.

The semisynthetic segment presently dominates the market attributable to the fact that the semisynthetic antibiotics possess improved coverage and effectiveness against a wide range of organisms. In addition, they can be administered either intravenously or orally or topically, and are lower cost to administer than other antibiotics, in some cases. However, the synthetic segment will grow with a highest rate during the forecast period, due to rise in need for synthetic membrane-targeted antibiotics due to antimicrobial resistance. Moreover, synthetic antibiotics have various advantages over existing antibiotics such as a broad spectrum of activity, no cross-resistance with the existing antibiotics, rapid bactericidal activity, and low probability to develop resistance.

Asia-Pacific was the leading revenue contributor to the global antibiotics market in 2017, and is expected to remain dominant throughout the forecast period, due to increase in consumption of antibiotics, easy availability of antibiotics, and rise in sale of over-the-counter drugs. However, LAMEA is expected to grow at the highest CAGR during the study period attributable to easy obtainability of antibiotics over the counter and no obligation on their usage in this region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to high prevalence of infectious diseases and rise in demand for antibiotics.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Antibiotics Market

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo